Johnson & Johnson reports ICOTYDE achieves 58% ACR20 response in biologic-naïve psoriatic arthritis
The Phase 3 ICONIC-PsA 1 study met its primary endpoint, with 58% of ICOTYDE-treated patients achieving an ACR20 response versus 41% of placebo at Week 16. Safety data through Week 24 showed no new safety signals and were consistent with the established safety profile of ICOTYDE.
Primary source
Company press release (PR Newswire), November 7, 2026
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Machine-summarized from the source above; not independently reported. How we use automation